Clinical Cancer Research Targets AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kelloff, G. J.
Right arrow Articles by Sullivan, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelloff, G. J.
Right arrow Articles by Sullivan, D. C.
Related Collections
Right arrow Clinical Research
Right arrow Clinical Research: Imaging, Diagnosis, and Prognosis
Clinical Cancer Research Vol. 11, 2785-2808, April 15, 2005
© 2005 American Association for Cancer Research

Perspective

Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

Gary J. Kelloff1, John M. Hoffman1, Bruce Johnson2, Howard I. Scher3, Barry A. Siegel4, Edward Y. Cheng5, Bruce D. Cheson6, Joyce O'Shaughnessy7, Kathryn Z. Guyton8, David A. Mankoff9, Lalitha Shankar1, Steven M. Larson3, Caroline C. Sigman8, Richard L. Schilsky10 and Daniel C. Sullivan1

Authors' Affiliations: 1 Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; 2 Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 3 Memorial Sloan-Kettering Cancer Center, New York, New York; 4 Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, St. Louis, Missouri; 5 Department of Orthopaedic Surgery, University of Minnesota and Orthopaedic Surgery Service, Fairview University Medical Center, Minneapolis, Minnesota; 6 Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia; 7 Baylor Charles A. Sammons Cancer Center, Dallas, Texas; 8 CCS Associates, Mountain View, California; 9 Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, Washington; and 10 Section of Hematology/Oncology, University of Chicago Pritzker School of Medicine, Chicago, Illinois

Requests for reprints: Gary J. Kelloff, Cancer Imaging Program, Division of Cancer Treatment and Diagnostics, National Cancer Institute, NIH, EPN 6130 Executive Boulevard, Suite 6058, Bethesda, MD 20892. Fax: 301-480-3507; E-mail: kelloffg{at}mail.nih.gov.

2-[18F]Fluoro-2-deoxyglucose positron emission tomography (FDG-PET) assesses a fundamental property of neoplasia, the Warburg effect. This molecular imaging technique offers a complementary approach to anatomic imaging that is more sensitive and specific in certain cancers. FDG-PET has been widely applied in oncology primarily as a staging and restaging tool that can guide patient care. However, because it accurately detects recurrent or residual disease, FDG-PET also has significant potential for assessing therapy response. In this regard, it can improve patient management by identifying responders early, before tumor size is reduced; nonresponders could discontinue futile therapy. Moreover, a reduction in the FDG-PET signal within days or weeks of initiating therapy (e.g., in lymphoma, non–small cell lung, and esophageal cancer) significantly correlates with prolonged survival and other clinical end points now used in drug approvals. These findings suggest that FDG-PET could facilitate drug development as an early surrogate of clinical benefit. This article reviews the scientific basis of FDG-PET and its development and application as a valuable oncology imaging tool. Its potential to facilitate drug development in seven oncologic settings (lung, lymphoma, breast, prostate, sarcoma, colorectal, and ovary) is addressed. Recommendations include initial validation against approved therapies, retrospective analyses to define the magnitude of change indicative of response, further prospective validation as a surrogate of clinical benefit, and application as a phase II/III trial end point to accelerate evaluation and approval of novel regimens and therapies.

Key Words: FDG-PET • molecular imaging • oncology • drug development




This article has been cited by other articles:


Home page
 JNMHome page
K. B. Contractor and E. O. Aboagye
Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 97S - 105S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
M. Wu
Real-Time Measurement of Mitochondrial Respiration and Glycolysis Rates of Cancer Cells in a Microplate
Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 295 - 300.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. K. Shankar, A. Van den Abbeele, J. Yap, R. Benjamin, S. Scheutze, and T.J. FitzGerald
Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology
Clin. Cancer Res., March 15, 2009; 15(6): 1891 - 1897.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
D. C. Sullivan
Anatomic and Functional Imaging Techniques for Response Assessment in Oncology
ASCO Educational Book, January 1, 2009; 2009(1): 119 - 122.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
B. E. Hillner, B. A. Siegel, A. F. Shields, D. Liu, I. F. Gareen, E. Hunt, and R. E. Coleman
Relationship Between Cancer Type and Impact of PET and PET/CT on Intended Management: Findings of the National Oncologic PET Registry
J. Nucl. Med., December 1, 2008; 49(12): 1928 - 1935.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Nahmias and L. M. Wahl
Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors
J. Nucl. Med., November 1, 2008; 49(11): 1804 - 1808.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Emmering, N. C. Krak, J. J. M. Van der Hoeven, M. D. Spreeuwenberg, J. W. R. Twisk, S. Meijer, H. M. Pinedo, and O. S. Hoekstra
Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology
Ann. Onc., September 1, 2008; 19(9): 1573 - 1577.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
P S MURPHY, T J McCARTHY, and A S K DZIK-JURASZ
The role of clinical imaging in oncological drug development
Br. J. Radiol., September 1, 2008; 81(969): 685 - 692.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. V. Frangioni
New Technologies for Human Cancer Imaging
J. Clin. Oncol., August 20, 2008; 26(24): 4012 - 4021.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
X. Jiang, H. Kenerson, L. Aicher, R. Miyaoka, J. Eary, J. Bissler, and R. S. Yeung
The Tuberous Sclerosis Complex Regulates Trafficking of Glucose Transporters and Glucose Uptake
Am. J. Pathol., June 1, 2008; 172(6): 1748 - 1756.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. J. Gillies, I. Robey, and R. A. Gatenby
Causes and Consequences of Increased Glucose Metabolism of Cancers
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 24S - 42S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Plathow and W. A. Weber
Tumor Cell Metabolism Imaging
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
P. T. Winnard Jr., A. P. Pathak, S. Dhara, S. Y. Cho, V. Raman, and M. G. Pomper
Molecular Imaging of Metastatic Potential
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 96S - 112S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. E. Hillner, B. A. Siegel, D. Liu, A. F. Shields, I. F. Gareen, L. Hanna, S. H. Stine, and R. E. Coleman
Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) Alone on Expected Management of Patients With Cancer: Initial Results From the National Oncologic PET Registry
J. Clin. Oncol., May 1, 2008; 26(13): 2155 - 2161.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
G. Williams and G. M. Kolodny
Method for Decreasing Uptake of 18F-FDG by Hypermetabolic Brown Adipose Tissue on PET
Am. J. Roentgenol., May 1, 2008; 190(5): 1406 - 1409.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
R. M. Sharkey, H. Karacay, S. Vallabhajosula, W. J. McBride, E. A. Rossi, C.-H. Chang, S. J. Goldsmith, and D. M. Goldenberg
Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model
Radiology, February 1, 2008; 246(2): 497 - 507.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
S. Assadian, A. Aliaga, R. F. Del Maestro, A. C. Evans, and B. J. Bedell
FDG-PET imaging for the evaluation of antiglioma agents in a rat model
Neuro-oncol, January 1, 2008; 10(3): 292 - 299.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens
Application of PET/CT in the Development of Novel Anticancer Drugs
Oncologist, January 1, 2008; 13(1): 25 - 38.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
J. M. Hoffman, S. S. Gambhir, and G. J. Kelloff
Regulatory and Reimbursement Challenges for Molecular Imaging
Radiology, December 1, 2007; 245(3): 645 - 660.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Seam, M. E. Juweid, and B. D. Cheson
The role of FDG-PET scans in patients with lymphoma
Blood, November 15, 2007; 110(10): 3507 - 3516.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir
Molecular Imaging Techniques in Body Imaging
Radiology, November 1, 2007; 245(2): 333 - 356.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
B. E. Hillner, D. Liu, R. E. Coleman, A. F. Shields, I. F. Gareen, L. Hanna, S. H. Stine, and B. A. Siegel
The National Oncologic PET Registry (NOPR): Design and Analysis Plan
J. Nucl. Med., November 1, 2007; 48(11): 1901 - 1908.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Sharkey, H. Karacay, W. J. McBride, E. A. Rossi, C.-H. Chang, and D. M. Goldenberg
Bispecific Antibody Pretargeting of Radionuclides for Immuno Single-Photon Emission Computed Tomography and Immuno Positron Emission Tomography Molecular Imaging: An Update
Clin. Cancer Res., September 15, 2007; 13(18): 5577s - 5585s.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. H. Hausner, D. DiCara, J. Marik, J. F. Marshall, and J. L. Sutcliffe
Use of a Peptide Derived from Foot-and-Mouth Disease Virus for the Noninvasive Imaging of Human Cancer: Generation and Evaluation of 4-[18F]Fluorobenzoyl A20FMDV2 for In vivo Imaging of Integrin {alpha}v{beta}6 Expression with Positron Emission Tomography
Cancer Res., August 15, 2007; 67(16): 7833 - 7840.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. P. Schuster
The Opportunities and Challenges of Developing Imaging Biomarkers to Study Lung Function and Disease
Am. J. Respir. Crit. Care Med., August 1, 2007; 176(3): 224 - 230.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. F. Prasanphanich, P. K. Nanda, T. L. Rold, L. Ma, M. R. Lewis, J. C. Garrison, T. J. Hoffman, G. L. Sieckman, S. D. Figueroa, and C. J. Smith
[64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues
PNAS, July 24, 2007; 104(30): 12462 - 12467.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
D. A. Torigian, S. S. Huang, M. Houseni, and A. Alavi
Functional Imaging of Cancer with Emphasis on Molecular Techniques
CA Cancer J Clin, July 1, 2007; 57(4): 206 - 224.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
J. M. Hoffman and S. S. Gambhir
Molecular Imaging: The Vision and Opportunity for Radiology in the Future
Radiology, July 1, 2007; 244(1): 39 - 47.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn
Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond
Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. Senzer, J. Nemunaitis, M. Nemunaitis, J. Lamont, M. Gore, H. Gabra, R. Eeles, N. Sodha, F. J. Lynch, L. A. Zumstein, et al.
p53 therapy in a patient with Li-Fraumeni syndrome
Mol. Cancer Ther., May 1, 2007; 6(5): 1478 - 1482.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
M. J. Lindsay, B. A. Siegel, S. R. Tunis, B. E. Hillner, A. F. Shields, B. P. Carey, and R. E. Coleman
The National Oncologic PET Registry: Expanded Medicare Coverage for PET Under Coverage with Evidence Development
Am. J. Roentgenol., April 1, 2007; 188(4): 1109 - 1113.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
M. Wu, A. Neilson, A. L. Swift, R. Moran, J. Tamagnine, D. Parslow, S. Armistead, K. Lemire, J. Orrell, J. Teich, et al.
Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells
Am J Physiol Cell Physiol, January 1, 2007; 292(1): C125 - C136.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. Nwogu, G. Fischer, D. Tan, M. Glinianski, D. Lamonica, and T. Demmy
Radioguided Detection of Lymph Node Metastasis in Non-Small Cell Lung Cancer
Ann. Thorac. Surg., November 1, 2006; 82(5): 1815 - 1820.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
V. Arienti, S. Pretolani, S. N. Goldberg, S. G. Silverman, D. A. Gervais, R. Lencioni, D. Sacks, and D. Dupuy
How to Report and Compare Complications of Image-guided Ablation Therapies: Comments on Seeding and the Use of a Sole Common Denominator for Liver Tumors.
Radiology, November 1, 2006; 241(2): 625 - 627.
[Full Text] [PDF]

Home page
 JNMHome page
W. J. McBride, P. Zanzonico, R. M. Sharkey, C. Noren, H. Karacay, E. A. Rossi, M. J. Losman, P.-Y. Brard, C.-H. Chang, S. M. Larson, et al.
Bispecific Antibody Pretargeting PET (ImmunoPET) with an 124I-Labeled Hapten-Peptide
J. Nucl. Med., October 1, 2006; 47(10): 1678 - 1688.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. S. El-Deiry, C. C. Sigman, and G. J. Kelloff
Imaging and Oncologic Drug Development
J. Clin. Oncol., July 10, 2006; 24(20): 3261 - 3273.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. M. Larson and L. H. Schwartz
18F-FDG PET as a Candidate for "Qualified Biomarker": Functional Assessment of Treatment Response in Oncology
J. Nucl. Med., June 1, 2006; 47(6): 901 - 903.
[Full Text] [PDF]

Home page
 aacredbookHome page
D. C. Sullivan
The Role of Molecular Imaging in Development of Novel Therapies
Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 133 - 135.
[Full Text] [PDF]

Home page
 JCOHome page
D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J.-F. Chatal
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
J. Clin. Oncol., February 10, 2006; 24(5): 823 - 834.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. D. Lee, W. I. Yang, Y. N. Park, K. S. Kim, J. S. Choi, M. Yun, D. Ko, T.-S. Kim, A. E.H. Cho, H. M. Kim, et al.
Different Glucose Uptake and Glycolytic Mechanisms Between Hepatocellular Carcinoma and Intrahepatic Mass-Forming Cholangiocarcinoma with Increased 18F-FDG Uptake
J. Nucl. Med., October 1, 2005; 46(10): 1753 - 1759.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Sharkey, H. Karacay, T. M. Cardillo, C.-H. Chang, W. J. McBride, E. A. Rossi, I. D. Horak, and D. M. Goldenberg
Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
Clin. Cancer Res., October 1, 2005; 11(19): 7109s - 7121s.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.